Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation.
Fiche publication
Date publication
juillet 2020
Journal
Cancer immunology, immunotherapy : CII
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François, Pr BORG Christophe, Dr FAGNONI Philippe, Pr NERICH Virginie, Pr WESTEEL Virginie, Dr THIERY-VUILLEMIN Antoine, Dr KROEMER Marie
Tous les auteurs :
Couchoud C, Fagnoni P, Aubin F, Westeel V, Maurina T, Thiery-Vuillemin A, Gerard C, Kroemer M, Borg C, Limat S, Nerich V
Lien Pubmed
Résumé
Scientific advances in the last decade have highlighted the use of immunotherapy, especially immune checkpoint inhibitors, to be an effective strategy in cancer therapy. However, these immunotherapeutic agents are expensive, and their use must take into account economic criteria. Thus, the objective of the present study was to systematically identify and review published EE related to the use of ipilimumab, nivolumab or pembrolizumab in melanoma, lung cancer, head and neck cancer or renal cell carcinoma, and to assess their quality.
Mots clés
Cost-effectiveness analysis, Cost-utility analysis, Economic evaluation, Immunotherapy, Melanoma, Quality-adjusted life years
Référence
Cancer Immunol. Immunother.. 2020 Jul 16;: